Actos 30 mg (Pioglitazone)
Actos 30 mg (Pioglitazone) is an oral antidiabetic agent that acts primarily by decreasing insulin resistance.
Following oral administration, in the fasting state, pioglitazone is first measurable in serum within 30 minutes, with peak concentrations observed within 2 hours. Food slightly delays the time to peak serum concentration to 3 to 4 hours, but does not alter the extent of absorption.
The mean apparent volume of distribution (Vd/F) of pioglitazone following single-dose administration is 0.63 + 0.41 (mean + SD) L/kg of body weight. Pioglitazone
is extensively protein bound (>99%) in human serum, principally to serum albumin. Pioglitazone also binds to other serum proteins, but with lower affinity. Metabolites M-III and M-IV also are extensively bound (>98%) to serum albumin.
Compared with normal controls, subjects with impaired hepatic function (Child-Pugh Grade B/C) have an approximate 45% reduction in pioglitazone and total pioglitazone mean peak concentrations but no change in the mean AUC values